These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36876583)

  • 1. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.
    Kopra EI; Ferris JA; Winstock AR; Kuypers KP; Young AH; Rucker JJ
    J Psychopharmacol; 2023 Jul; 37(7):733-748. PubMed ID: 36876583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.
    Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF
    J Psychoactive Drugs; 2023; 55(1):73-84. PubMed ID: 35001856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
    Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR
    Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
    Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS
    BMJ; 2024 Aug; 386():e078607. PubMed ID: 39168500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
    Ezeaka UC; Kim HJJ; Laprairie RB
    Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic use and intimate partner violence: The role of emotion regulation.
    Thiessen MS; Walsh Z; Bird BM; Lafrance A
    J Psychopharmacol; 2018 Jul; 32(7):749-755. PubMed ID: 29807492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.
    Hovmand OR; Poulsen ED; Arnfred S
    J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
    Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
    Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular insights into psychedelic drug action.
    Slocum ST; DiBerto JF; Roth BL
    J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic medicines for mood disorders: current evidence and clinical considerations.
    Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D
    Curr Opin Psychiatry; 2022 Jan; 35(1):22-29. PubMed ID: 34855694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.